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Objectives: The aim of this research is to assess the humanistic and economic 
burden of focal drug-refractory epilepsy in Europe. MethOds: A PubMed litera-
ture review was performed to identify publications from January 2004 to December 
2014 on prevalence and incidence, impact on quality of life and associated costs of 
epilepsy. Results: In Europe around 6 million people have epilepsy, with 30-45% 
of patients being drug-refractory and 70% of those having focal drug-refractory 
epilepsy. The prevalence and incidence rate of epilepsy is 457 and 43.87 per 100.000 
persons, respectively. Epilepsy is associated with psychiatric comorbidities, chronic 
somatic conditions, significantly lower quality of life and 2-11 times higher all-cause 
mortality than the general population. In 2004 health care expenditures for the 
treatment of epilepsy accounted for 0.2% of the total European national income 
and the annual cost per patient varied from € 2.000 to € 11.500. In 2010, the yearly 
cost of epilepsy ranged from € 13.8 to € 20 billion. The cost of epilepsy depends on the 
severity and frequency of seizures and if patients are drug-refractory (20% to 40% 
of drug-refractory patients account for 80% of the costs). The main cost drivers of 
epilepsy treatment are hospitalizations, antiepileptic drug costs and indirect costs 
(due to high unemployment rate; 46% compared with 19% for the matched control 
population). Standard therapy for drug-refractory focal epilepsy is open surgery 
which is highly effective but also highly invasive and requires strict screening cri-
teria. Minimally invasive surgical techniques are an alternative to open surgery and 
have shown promising clinical benefits with lower neurological impairment and less 
hospital stays compared with open surgery. cOnclusiOns: This data highlights the 
high humanistic and economic burden of focal drug-refractory epilepsy in Europe, 
and the need for new procedures to improve health outcomes and reduce health 
care resource utilization.
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Objectives: In recent years, health technology assessment (HTA) agencies have 
encountered substantial technical challenges in assessing the relative value of new 
therapies for multiple sclerosis (MS), potentially delaying patient access to promis-
ing drugs. We assessed the impact of contrasting approaches to HTA in Germany and 
the UK on patient access to new therapies for MS. MethOds: Technology apprais-
als performed by the National Institute for Health and Care Excellence (NICE) and 
Institute for Quality and Efficiency in Healthcare (IQWiG) since the Pharmaceuticals 
Market Reorganisation Act (AMNOG) in January 2011 were assessed. Quantitative 
and qualitative assessment of appraisal decisions in the context of overall assess-
ment processes, evidence requirements and anticipated patient impact were con-
ducted for each technology. Results: Three therapies have been assessed by both 
NICE and IQWiG (fingolimod, dimethyl fumarate and teriflunomide); both bodies 
have assessed additional therapies independently. All three technologies were rec-
ommended by NICE in restricted patient populations, with an agreed price discount. 
NICE faced considerable technical methodological challenges during the assess-
ment process, including comparator selection (blended versus pair-wise incremen-
tal analyses), assessment versus non-cost-effective beta-interferon comparators 
and appropriate use of mixed treatment comparisons. In some cases, modelling 
assumptions accepted in previous appraisals were criticised by NICE in subsequent 
submissions. By contrast, IQWiG and the Federal Joint Committee (G-BA) concluded 
that all drugs provided no proven clinical benefit, except fingolimod (minor benefit 
in limited subset of patients with rapidly-evolving severe relapsing-remitting MS), 
due to limited clinical data versus IQWiG-specified comparators. cOnclusiOns: 
Patients in Germany can access all three therapies, consistent with their market-
ing authorisations, despite the negative IQWiG appraisal recommendations. In the 
UK, however, fewer patient subgroups can access the same therapies, partly due to 
evolving methodologies used by NICE to assess cost-effectiveness. Greater under-
standing of challenges that impact HTA decisions may facilitate earlier patient 
access to promising MS therapies.
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Objectives: The primary objective of this analysis was to model the clinical and 
cost effectiveness of glatiramer acetate (GA) using 6-year data from the UK Multiple 
Sclerosis Risk Sharing Scheme (RSS). MethOds: A continuous Markov model was 
developed to assess mean Expanded Disability Status Scale (EDSS) and utility at 
year-6 and to determine whether this was consistent with a cost-effective target of 
£36,000 per quality-adjusted life year (QALY) projected over 20 years. In populating 
the model, data from patients fulfilling the Association of British Neurologists (ABN) 
2001 guidelines were analysed together with matched patient data from the British 
Columbia Multiple Sclerosis database (BCMS) as a comparator. Primary outcome 
was the progression ratio, measured both as EDSS score and utility, determined for 
the GA treated group by adjusting within the model the theoretical ratio imposed 
on the comparator patients until the difference between the theoretical and actual 
treated groups was mathematically zero. This effective ratio was input into the cost-
effectiveness calculator part of the model to determine the cost per QALY. Results: 
978 patients starting GA were enrolled (F: 755, M: 223), with an average age of 30.0 
years at entry. 898 BCMS patients were included as comparators. GA patients had 
a mean follow-up of 5.23 years (SD 1.33). The Markov model showed 30.3% slower 
EDSS progression for the GA cohort than predicted for untreated controls (progres-
sion ratio: 69.7%). Utility ratios were consistent with cost-effectiveness (ratio: 44.2%) 
for GA. Cost per QALY for GA was well below the target of £36,000. cOnclusiOns: 
utilization and costs in individuals with probable DMD. MethOds: We identified 
males aged 5-25 with at least one claim for hereditary progressive muscular dys-
trophy between 11/01/2011 and 10/31/2013 (date of first claim = index) from a US 
administrative claims database. Patients were required to be continuously enrolled 
with pharmacy benefits for 12 months after index date. Cardiac drugs, gastroin-
testinal drugs, and adrenals (including steroids) were evaluated in the 12 months 
after index. Number of inpatient and ER admissions, number of non-ER outpatient 
claims and prescriptions, as well as healthcare costs (overall and DMD-specific) 
were evaluated in the 12 months after index. Results: A total of 1,773 males with 
probable DMD were identified (mean age 14.5). We observed 368 (31%) patients on 
adrenals, 356 (30%) on cardiac drugs, and 124 (10%) with gastrointestinal drug use 
during follow-up. In the year after index, 16% had at least one inpatient admission 
(13% DMD-specific admissions), and 29% had at least one ER admission (13% DMD-
specific). The average number of outpatient claims was 79.8 (33.3 DMD-specific), and 
average number of prescriptions was 17.8. Mean annual costs were $34,381 ($17,581 
DMD-specific). cOnclusiOns: Healthcare utilization and costs were substantial, 
and are likely to be underestimated due to inclusion of milder non-DMD forms of 
muscular dystrophy in the present study. Although DMD is a rare disease, the health 
burden and societal costs are considerable. New therapies to address the underlying 
disease are urgently needed.
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Objectives: Understanding the health care costs associated with Multiple sclerosis 
(MS) in the geriatric population is not well studied. The objective of this study is 
to assess the health care costs associated with geriatric patients diagnosed with 
MS and taking disease modifying therapies (DMTs) in the US. MethOds: A large 
US administrative retrospective claims database was used to identify patients 
diagnosed with MS and were prescribed DMTs between January 2010 to December 
2012 were included in the study. All patients were ≥ 65 years of age and continu-
ously enrolled in the same health plan for at least a year. Descriptive statistics and 
chi-square tests were performed on the data and statistical significance level was 
set a priori at 0.05. Results: There were a total of 88,921 patients that met the 
study inclusion criteria. Majority (66.9%) of the patients was taking subcutaneous 
injections (SC), 31.2% were taking IV/IM (IVM)and 1.9% was taking oral (OR) DMTs 
(p< 0.001). Patients on average were charged $4227.9± 2354.2 with a significant differ-
ence (p< 0.001) between the three drug groups (OR $5087 vs SC $4225 vs IVM $4188). 
However, the mean allowed amount by the health plan was $3692.5 ± 1915.5 and 
the actual paid amount was $3587.1 ± 1921.5 with a significant difference between 
the groups (p< 0.001). On average, patient’s deductible was $17.9 ± 207.8 and patient 
co-payment was $83.0 ± 304.3 with a difference between the groups (p< 0.001). For 
patients whose prescription was on their health plans formulary were charged lower 
($4187 vs $4246, p< 0.05) and paid lower co-payment ($78 vs $97, p< 0.001) than who 
were not. There was a significant variation in the cost of the treatments in different 
regions in the USA (p< 0.001). cOnclusiOns: The overall costs for oral DMTs were 
higher than SC and IVM DMTs.
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Objectives: There are currently several pharmaceutical options for multiple scle-
rosis (MS), some introduced recently and some more coming in the future. They are 
characterized by different modes of action, schemes of administration and, ulti-
mately, costs. MS resources management is thus complex and rely on proper interac-
tion between stakeholders – hospital pharmacists, MS department heads, hospital 
top management, local health representatives, heads of regional pharmaceutical 
policy. This is particularly true in Italy, a federal and delocalised setting comprising 
local, provincial, regional, and national decision makers. The aim of this work was 
to design a tool to explore the financial implications and ultimately align decision 
makers. Informed choices might save resources and support the adoption of inno-
vative treatments, thus contributing to overall sustainability and equity in patient 
access. MethOds: We developed a dynamic user-friendly tool in Microsoft Excel® 
with VBA® macros. The flow of the analysis is stepwise and comprises, on top of 
adherence, variables usually excluded from standard budget impact such as intra- 
and inter-class switches, potential wash out period, as well as drop-out rates. All 
variables can be modified or excluded by users since default values can be restored 
at any time. The tool is open and can accommodate future treatments. Results: 
The tool assesses the financial impact of alternative choices in a comprehensive 
manner since results can be displayed with the desired level of detail – cumulative 
or annual, overall or by treatment line and/or cost item. cOnclusiOns: This is an 
example of how to match the required level of information to specific end-users, 
encouraging both discussion and decision making in the best interest of patients. 
This is a prerequisite in multifaceted realities like Italy but it could assist in many 
other settings where stakeholders need to align to each other in order to forecasts 
accurately budget allocation.
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possession ratio (MPR) and proportion of days covered (PDC); and persistence, days to 
the first ≥ 30-day gap on index DMT. Outcomes were compared between the GA40 and 
oral DMT cohorts. Results: The final sample was 1,779 patients (232 GA40, 1547 oral 
DMT), with mean age 45.5 years and 77.9% female. The GA40 and oral DMT cohorts 
had 0.39 versus 1.07 discontinuations/person-year, respectively, for an incidence rate 
ratio of 2.75 (p< 0.001). Kaplan-Meier analysis showed that GA40 cohort was more per-
sistent per post-index 90-day interval (p< 0.001). Mean (standard deviation) MPR and 
PDC in the GA40 cohort were 0.88 (0.18) and 0.87 (0.20), respectively, versus 0.84 (0.18) 
and 0.70 (0.30) in the oral DMT cohort (both p< 0.001). To account for differences in 
follow-up, MPR was examined in patients with maximum 210, 270, and 330 post-index 
days. Mean MPR was 0.90 (0.16) in the GA40 cohort with ≤ 210 post-index days versus 
0.86 (0.16) for oral DMT (p< 0.05); mean MPR was not significantly different between 
the cohorts with maximum 270 or 330 post-index days. Mean PDC was higher in the 
GA40 cohort in all comparisons (all p< 0.001). cOnclusiOns: MS patients starting 
GA40 were more persistent and at least as adherent (similar on MPR and better on 
PDC) compared with those starting oral DMTs, possibly due to GA40’s safety profile 
and less-frequent dosing schedule.
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Objectives: DMTs to manage RRMS patients have traditionally been injectables. 
With the introduction of new oral DMTs, a better understanding of the shift in treat-
ment patterns and their impact on patient disease burden is needed. The objective 
of this study was to assess the characteristics of RRMS patients taking injectable 
and oral DMTs in the EU (5EU: UK/France/Germany/Italy/Spain). MethOds: A multi-
center retrospective chart-review study of RRMS patients was conducted in the 5EU 
in 4Q2014 to collect de-identified data on diagnosis, clinical status, and treatment 
patterns. Physicians were screened for duration of practice (≥ 3yrs) and patient vol-
ume (≥ 15 MS patients/mo) and recruited from a large panel to be geographically rep-
resentative. Medical charts of the next 10 consecutive MS patients were abstracted. 
RRMS patients taking an injectable (INJ) or oral DMT were analyzed. Results: 
1394 eligible RRMS patients were included in the analysis(INJ:64%; Oral:36%). 
Patient characteristics were(INJ/Oral):age:36/38yrs, female:65%/65%, time since 
diagnosis:53/59mo, time between diagnosis and initiation of first DMT:6.7/7.2mo, 
percent on first, second, and third line DMT were(INJ/Oral):84%/30%, 14%/50%, and 
2%/16%; time on current DMT(INJ/Oral):40mo/9mo. Reasons for current DMT ini-
tiation included(INJ/Oral):efficacy against relapses(26%/26%)/efficacy for disease 
progression(12%/14%)/efficacy in early MS(17%/5%)/patient decision(10%/7%)/
oral administration (0%/28%). Patient JCV status(INJ/Oral):positive-5%/18% & not 
tested-75%/63%; number of gadolinium-enhanced & T2 lesions:0.6/1.0 & 8.8/10.1; 
percent with ≥ 1 relapse in past 12mo:43%/65%; percent with Expanded Disability 
Status Scale score of ≥ 4.5:15%/31%; percent with moderate-to-severe disability per 
physician judgment:17%/33%; percent with active or highly active disease per phy-
sician judgment:39%/57%; percent with moderate-to-severe disease per physician 
judgment:26%/52%. cOnclusiOns: In this cohort of RRMS patients, physicians 
initiated oral DMTs predominantly as second or third-line treatment, and these 
patients may have higher disease burden compared to those receiving injectable 
DMTs. Further research is needed to evaluate the observed treatment patterns and 
treatment sequencing strategies to alleviate patient burden.
Using 6-year data and a 20-year time horizon, this model projected that the long-
term efficacy of GA in terms of disability in patients with relapsing multiple sclerosis 
was greater than anticipated, with the results also signifying cost-effectiveness of 
treatment greater than predicted at the outset of the RSS.
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Objectives: Compare the characteristics of RRMS patients treated with DMTs in 
EU and US. MethOds: A multi-center retrospective chart-review study of RRMS 
patients was conducted in US and EU in 4Q2014 to collect de-identified data on 
diagnosis, clinical status, and treatment patterns. Neurologists were screened for 
practice duration (≥ 3yrs) and patient volume (≥ 15 MS patients/mo) and recruited 
from a large panel to be geographically representative in EU (5EU:UK/Germany/
France/Italy/Spain) and US. Neurologists abstracted de-identified data from next 10 
consecutive MS patients. RRMS patients taking injectable(INJ), oral, or infusible(INF) 
DMTs were analyzed, comparing 5EU and US. Results: 1601 (INJ:56%/Oral:31%/
INF:12%) and 640 (INJ:51%/Oral:41%/INF:8%) eligible RRMS patient charts were evalu-
ated from EU and US respectively. Distribution of current DMT treatment-line was 
(5EU/US;% patients)- 1st-line:INJ-84/77, oral-30/34, INF-28/22; 2nd-line: INJ-14/19, 
oral-50/50, INF-54/46; 3rd-or-more-line:INJ-3/5, oral-20/16, INF-18/32. Duration of 
current treatment was (5EU/US;months): INJ-39.5/50.3, oral-9.5/12.4, INF-19.1/25.8. 
Top-4 reasons for current treatment-initiation was (5EU/US;% patients)- efficacy 
for relapses:INJ-26/21, oral-26/15, INF-48/15; efficacy for disease progression: INJ-
12/21, oral-14/19, INF-30/67; efficacy for early MS/CIS:INJ-17/19, oral-5/5, INF-2/7; 
patient decision:INJ-10/12, oral-7/13, INF-2/6. Among those on oral DMTs, 28%/31% 
in EU/US initiated treatment because of mode of administration. Current patient 
disease severity per physician judgment was (5EU/US;% patients)- mild:INJ-73/72, 
oral-47/53, INF-21/19; moderate: INJ-25/27, oral-47/44, INF-61/69; severe:INJ-1/0, 
oral-5/2, INF-17/13. Latest mean EDSS scores were (5EU/US): INJ-2.0/1.9, oral-2.7/2.7, 
INF-3.7/3.8. Disease relapses suffered in the last 12-month was (5EU/US;% patients)- 
none:INJ-57/58, oral-35/42, INF-42/44; one:INJ-30/27, oral-42/34, INF-27/37; two-or-
more: INJ-13/14, oral-23/24, INF-32/19. Gd-enhanced lesions in recent cranial-MRI 
were (5EU/US;mean): INJ-0.6/0.6, oral-1.0/0.9, INF-1.5/1.0. T2-lesions in recent cranial-
MRI were (5EU/US;mean): INJ-8.8/7.8, oral-10.1/8.4, INF-14.6/11.9. cOnclusiOns: In 
this study cohort, clinical characteristics and disease burden varied by geography 
slightly, but more so, based on the different modes of DMT administration.
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Objectives: To compare adherence to glatiramer acetate 40 mg (GA40) and oral dis-
ease-modifying therapies (DMTs; fingolimod, teriflunomide, dimethyl fumarate) using 
a US administrative claims database. MethOds: Retrospective claims data analysis 
of commercial enrollees from a large US health plan who initiated GA40 or oral DMTs 
from April 2013–June 2014; DMT initiation was the index date. Patients were ≥ 18 years 
old, enrolled 6 months pre-index and ≥ 3 months post-index, and diagnosed with 
multiple sclerosis (MS). Key outcomes were: adherence, measured with medication 
